{"id":15849,"date":"2026-03-25T16:52:51","date_gmt":"2026-03-25T20:52:51","guid":{"rendered":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/?p=15849"},"modified":"2026-06-03T09:47:35","modified_gmt":"2026-06-03T13:47:35","slug":"lys-therapeutics-2","status":"publish","type":"post","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/lys-therapeutics-2\/","title":{"rendered":"LYS THERAPEUTICS"},"content":{"rendered":"\n
\"\"\/<\/div><\/div>
<\/div><\/div>
\n

LYS THERAPEUTICS<\/h1><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n

Biotech<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Created in 2021<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

11-20 employees<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n

First-in-class biotherapies for neurological diseases<\/mark><\/strong><\/h3><\/div>\n\n\n\n
\n
Stroke<\/a><\/div>\n\n\n\n
Multiple Sclerosis<\/a><\/div>\n\n\n\n
Neurology<\/a><\/div>\n\n\n\n
CNS<\/a><\/div>\n<\/div>\n\n\n\n

Lys Therapeutics is a late preclinical-stage biotechnology company developing first-in-class monoclonal antibodies to treat patients suffering from severe neurodegenerative and neurovascular diseases with high unmet medical needs. The company targets upstream disease biology common to multiple major neurological indications, at the intersection of neurovascular dysfunction, neuroinflammation, and excitotoxicity.<\/mark><\/p>\n\n\n\n

Its lead candidate, LYS241, is a fully humanized monoclonal antibody with a unique mode of action that selectively blocks the pathological interaction between tissue plasminogen activator (tPA) and NMDAr, while preserving normal receptor function. By uncoupling this key neurovascular axis, LYS241 simultaneously restores blood-brain barrier integrity, reduces neuroinflammation, and protects both vascular and neuronal compartments.<\/mark><\/p>\n\n\n\n

With operations in Lyon and Caen (France) and strong collaborations with leading international academic institutions, Lys Therapeutics is advancing a pipeline-in-a-drug strategy centered on LYS241. The company is supported by prestigious partners including The Michael J. Fox Foundation, Bpifrance, and leading private investors.<\/mark><\/p>\n\n\n\n

By targeting a unifying neurovascular mechanism, Lys Therapeutics aims to develop disease-modifying therapies capable of transforming outcomes across a broad spectrum of neurological diseases.<\/mark><\/p>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n

CONTACT INFORMATION<\/mark><\/strong><\/h3><\/div>\n\n\n\n

Manuel BLANC<\/strong><\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n